Annual report

Period2022-01-01 → 2022-12-31

Filed2023-03-27

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 137

Metric	Value	Period	Scope	Source row
Revenue	¥1.4bn	2022-01-01 → 2022-12-31	Cons.	Net sales
Revenue	¥2.0bn	2021-01-01 → 2021-12-31	Cons.	Net sales
Revenue	¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥3.2bn	2019-01-01 → 2019-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥755m	2018-01-01 → 2018-12-31^d	Cons.	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Operating income
Operating income	−¥531m	2021-01-01 → 2021-12-31	Cons.	Operating income
Ordinary income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Ordinary income
Ordinary income	−¥523m	2021-01-01 → 2021-12-31	Cons.	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥957m	2019-01-01 → 2019-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Income before income taxes
Profit before tax	−¥532m	2021-01-01 → 2021-12-31	Cons.	Income before income taxes
Net income (owners)	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥828m	2019-01-01 → 2019-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss
Net income	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss
Total assets	¥4.3bn	at 2022-12-31	Cons.	Assets
Total assets	¥5.4bn	at 2021-12-31	Cons.	Assets
Total assets	¥4.8bn	at 2020-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥5.4bn	at 2019-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Cons.	Total assets (5-year summary)
Total liabilities	¥625m	at 2022-12-31	Cons.	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Cons.	Liabilities
Net assets / equity	¥3.6bn	at 2022-12-31	Cons.	Net assets
Net assets / equity	¥4.3bn	at 2021-12-31	Cons.	Net assets
Net assets / equity	¥3.8bn	at 2020-12-31^d	Cons.	Net assets
Net assets / equity	¥3.9bn	at 2019-12-31^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥887m	at 2018-12-31^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥3.4bn	at 2022-12-31	Cons.	Cash and deposits
Cash and deposits	¥3.8bn	at 2021-12-31	Cons.	Cash and deposits
Cash & equivalents	¥3.4bn	at 2022-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥3.8bn	at 2021-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.3bn	at 2020-12-31^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.9bn	at 2019-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥1.4bn	at 2018-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	−¥708m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.5bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.3bn	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥1.5bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	−¥1.1bn	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥126m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥42m	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥70m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥41m	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥58m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	¥367m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥1.1bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥724m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥2.1bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥688m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥-99.1	2022-01-01 → 2022-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-42.1	2021-01-01 → 2021-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-90.33	2020-01-01 → 2020-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥76.05	2019-01-01 → 2019-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-125.02	2018-01-01 → 2018-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥74.51	2019-01-01 → 2019-12-31^d	Cons.	Diluted earnings per share (5-year summary)
Net assets per share	¥255.04	at 2022-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥323.54	at 2021-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥308.05	at 2020-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥329.86	at 2019-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥86.83	at 2018-12-31^d	Cons.	Net assets per share (5-year summary)
Equity ratio	85.0%	at 2022-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.3%	at 2021-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.0%	at 2020-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	71.5%	at 2019-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	49.7%	at 2018-12-31^d	Cons.	Equity to asset ratio (5-year summary)
ROE	35.1%	2019-01-01 → 2019-12-31^d	Cons.	Rate of return on equity (5-year summary)
Employees	65	at 2022-12-31	Cons.	Number of employees
Employees	64	at 2021-12-31	Cons.	Number of employees
Employees	64	at 2020-12-31^d	Cons.	Number of employees
Employees	63	at 2019-12-31^d	Cons.	Number of employees
Employees	62	at 2018-12-31^d	Cons.	Number of employees
Revenue	¥1.2bn	2022-01-01 → 2022-12-31	Standalone	Net sales
Revenue	¥1.9bn	2021-01-01 → 2021-12-31	Standalone	Net sales
Revenue	¥1.0bn	2020-01-01 → 2020-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥3.1bn	2019-01-01 → 2019-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥641m	2018-01-01 → 2018-12-31^d	Standalone	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Standalone	Operating income
Operating income	−¥558m	2021-01-01 → 2021-12-31	Standalone	Operating income
Ordinary income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Ordinary income
Ordinary income	−¥549m	2021-01-01 → 2021-12-31	Standalone	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥874m	2019-01-01 → 2019-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Income before income taxes
Profit before tax	−¥558m	2021-01-01 → 2021-12-31	Standalone	Income before income taxes
Net income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Profit loss
Net income	−¥556m	2021-01-01 → 2021-12-31	Standalone	Profit loss
Net income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Net income loss (5-year summary)
Net income	¥746m	2019-01-01 → 2019-12-31^d	Standalone	Net income loss (5-year summary)
Net income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Net income loss (5-year summary)
Total assets	¥4.0bn	at 2022-12-31	Standalone	Assets
Total assets	¥5.3bn	at 2021-12-31	Standalone	Assets
Total assets	¥4.7bn	at 2020-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥5.3bn	at 2019-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Standalone	Total assets (5-year summary)
Total liabilities	¥607m	at 2022-12-31	Standalone	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Standalone	Liabilities
Net assets / equity	¥3.4bn	at 2022-12-31	Standalone	Net assets
Net assets / equity	¥4.2bn	at 2021-12-31	Standalone	Net assets
Net assets / equity	¥3.7bn	at 2020-12-31^d	Standalone	Net assets
Net assets / equity	¥3.8bn	at 2019-12-31^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥900m	at 2018-12-31^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥3.1bn	at 2022-12-31	Standalone	Cash and deposits
Cash and deposits	¥3.6bn	at 2021-12-31	Standalone	Cash and deposits
EPS (basic)	¥-103.2	2022-01-01 → 2022-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-43.83	2021-01-01 → 2021-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-91.84	2020-01-01 → 2020-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥68.47	2019-01-01 → 2019-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-123.85	2018-01-01 → 2018-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥67.08	2019-01-01 → 2019-12-31^d	Standalone	Diluted earnings per share (5-year summary)
Net assets per share	¥240.82	at 2022-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥314.45	at 2021-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥301.39	at 2020-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥323.68	at 2019-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥88.07	at 2018-12-31^d	Standalone	Net assets per share (5-year summary)
Equity ratio	84.6%	at 2022-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.9%	at 2021-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.7%	at 2020-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	71.1%	at 2019-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.1%	at 2018-12-31^d	Standalone	Equity to asset ratio (5-year summary)
ROE	32.0%	2019-01-01 → 2019-12-31^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	14,218,300	at 2022-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	13,313,400	at 2021-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	12,407,100	at 2020-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	11,654,500	at 2019-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	10,139,600	at 2018-12-31^d	Standalone	Total number of issued shares (5-year summary)
Employees	62	at 2022-12-31	Standalone	Number of employees
Employees	61	at 2021-12-31	Standalone	Number of employees
Employees	61	at 2020-12-31^d	Standalone	Number of employees
Employees	60	at 2019-12-31^d	Standalone	Number of employees
Employees	58	at 2018-12-31^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 42

Segment	Item	Period	Value
Reconciling Itemsreconciling	segment assets	at 2022-12-31	¥3.2bn
Drug Discovery Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥68m
Drug Discovery Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥13m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	34 pure
Drug Discovery Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	segment assets	at 2022-12-31	¥373m
Drug Discovery Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	−¥1.7bn
Drug Discovery Support Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥58m
Drug Discovery Support Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥21m
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	23 pure
Drug Discovery Support Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	segment assets	at 2022-12-31	¥685m
Drug Discovery Support Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	¥453m
—segment total	capex	2022-01-01 → 2022-12-31	¥126m
—segment total	depreciation	2022-01-01 → 2022-12-31	¥34m
—segment total	revenue	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	revenue external	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	segment assets	at 2022-12-31	¥1.1bn
—segment total	segment profit	2022-01-01 → 2022-12-31	−¥1.3bn
Reconciling Itemsreconciling	segment assets	at 2021-12-31	¥3.7bn
Drug Discovery Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥14m
Drug Discovery Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥5m
Drug Discovery Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	segment assets	at 2021-12-31	¥1.2bn
Drug Discovery Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	−¥820m
Drug Discovery Support Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥12m
Drug Discovery Support Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥15m
Drug Discovery Support Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	segment assets	at 2021-12-31	¥497m
Drug Discovery Support Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	¥289m
—segment total	capex	2021-01-01 → 2021-12-31	¥26m
—segment total	depreciation	2021-01-01 → 2021-12-31	¥19m
—segment total	revenue	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	revenue external	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	segment assets	at 2021-12-31	¥1.7bn
—segment total	segment profit	2021-01-01 → 2021-12-31	−¥531m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	33 pure
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	21 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,303

Item	Context	Value	Unit
Current liabilities	Prior1YearInstant	774655000	JPY
Current liabilities	CurrentYearInstant	436407000	JPY
Bonds payable	Prior1YearInstant	32000000	JPY
Bonds payable	CurrentYearInstant	－	JPY
Long term loans payable	Prior1YearInstant	268390000	JPY
Long term loans payable	CurrentYearInstant	148402000	JPY
Asset retirement obligations ncl	Prior1YearInstant	37434000	JPY
Asset retirement obligations ncl	CurrentYearInstant	38040000	JPY
Other ncl	Prior1YearInstant	4508000	JPY
Other ncl	CurrentYearInstant	1759000	JPY
Noncurrent liabilities	Prior1YearInstant	342332000	JPY
Noncurrent liabilities	CurrentYearInstant	188201000	JPY
Liabilities	Prior1YearInstant	1116988000	JPY
Liabilities	CurrentYearInstant	624609000	JPY
Capital stock	Prior1YearInstant	1056953000	JPY
Capital stock	CurrentYearInstant	1382246000	JPY
Capital surplus	Prior1YearInstant	4808163000	JPY
Capital surplus	CurrentYearInstant	5133456000	JPY
Retained earnings	Prior1YearInstant	-1572951000	JPY
Retained earnings	CurrentYearInstant	-2922490000	JPY
Treasury stock	Prior1YearInstant	-222000	JPY
Treasury stock	CurrentYearInstant	-222000	JPY
Shareholders equity	Prior1YearInstant	4291942000	JPY
Shareholders equity	CurrentYearInstant	3592988000	JPY
Valuation difference on available for sale securities	Prior1YearInstant	-630000	JPY
Valuation difference on available for sale securities	CurrentYearInstant	-2373000	JPY
Deferred gains or losses on hedges	Prior1YearInstant	6578000	JPY
Deferred gains or losses on hedges	CurrentYearInstant	615000	JPY
Foreign currency translation adjustment	Prior1YearInstant	7841000	JPY
Foreign currency translation adjustment	CurrentYearInstant	33225000	JPY
Valuation and translation adjustments	Prior1YearInstant	13789000	JPY
Valuation and translation adjustments	CurrentYearInstant	31467000	JPY
Subscription rights to shares	Prior1YearInstant	9840000	JPY
Subscription rights to shares	CurrentYearInstant	17388000	JPY
Net assets	Prior1YearInstant	4315572000	JPY
Net assets	CurrentYearInstant	3641844000	JPY
Liabilities and net assets	Prior1YearInstant	5432560000	JPY
Liabilities and net assets	CurrentYearInstant	4266453000	JPY
Net sales	Prior1YearDuration	2017529000	JPY
Net sales	CurrentYearDuration	1386748000	JPY
Cost of sales	Prior1YearDuration	135387000	JPY
Cost of sales	CurrentYearDuration	171550000	JPY
Gross profit	Prior1YearDuration	1882141000	JPY
Gross profit	CurrentYearDuration	1215197000	JPY
Selling general and administrative expenses	Prior1YearDuration	2413277000	JPY
Selling general and administrative expenses	CurrentYearDuration	2485086000	JPY
Operating income	Prior1YearDuration	-531135000	JPY
Operating income	CurrentYearDuration	-1269888000	JPY
Interest income noi	Prior1YearDuration	107000	JPY
Interest income noi	CurrentYearDuration	147000	JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2021-12-31	pass
balance sheet identity	consolidated 2022-12-31	pass
balance sheet identity	non_consolidated 2021-12-31	pass rounding
balance sheet identity	non_consolidated 2022-12-31	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2020-12-31	pass
statement vs summary · net assets	consolidated 2021-12-31	pass
statement vs summary · net assets	consolidated 2022-12-31	pass
statement vs summary · net assets	non_consolidated 2020-12-31	pass
statement vs summary · net assets	non_consolidated 2021-12-31	pass
statement vs summary · net assets	non_consolidated 2022-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · operating cash flow	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · operating cash flow	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	non_consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	non_consolidated 2022-01-01/2022-12-31	pass
statement vs summary · total assets	consolidated 2021-12-31	pass
statement vs summary · total assets	consolidated 2022-12-31	pass
statement vs summary · total assets	non_consolidated 2021-12-31	pass
statement vs summary · total assets	non_consolidated 2022-12-31	pass